CRP and myocardial infarction: This hypothesis is also consistent with the results from the CANTOS trial, which demonstrates that the monoclonal antibody targeting interleukin-1β canakinumab has clinical benefits in reducing adverse cardiovascular events in the MI patients with residual inflammatory risks (median hs-CRP level 4.2 mg/L at entry) (18).